Obesity is increasingly recognized as a chronic relapsing disease that poses significant morbidity, mortality, and health care costs. Recent advancements in obesity pharmacotherapy are shifting the focus from mere weight reduction to a more comprehensive approach that addresses multiple obesity-related complications.
The authors conducted a systematic literature search in the Medline database, focusing on new-generation obesity pharmacotherapies published between 2021 and 2026. They included phase 2 and 3 clinical trials that evaluated emerging treatments in adults, specifically those reporting outcomes related to weight loss and obesity-related complications.
Among the promising treatments are entero-pancreatic hormone-based therapies that target pathways involving glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, amylin, and glucagon. These therapies have shown substantial efficacy, not only in weight reduction but also in improving metabolic health. For instance, GLP-1 based agents typically achieve weight loss of approximately 10-15%, while multi-pathway agents have demonstrated even greater efficacy.
Notably, agents such as Tirzepatide, CagriSema, and amycretin have achieved weight reductions exceeding 20%, with the triple agonist retatrutide producing reductions greater than 25%. Beyond weight loss, these agents have been associated with improvements in glycemia, diabetes prevention, and various organ-specific benefits. These benefits include reduced cardiovascular events, improved symptoms of heart failure, decreased severity of obstructive sleep apnea, and slowing the progression of chronic kidney disease. Additionally, they have been shown to alleviate pain associated with osteoarthritis.
The conclusion drawn from this review is that next-generation obesity pharmacotherapies represent a significant advancement in the management of obesity. This approach supports a treat-to-target strategy that prioritizes improvements in obesity-related complications and overall metabolic health. However, effective implementation will necessitate individualized therapy and careful consideration of long-term safety, access, and equitable delivery of care.
What this study does not show
This review does not establish specific clinical outcomes from the use of the discussed pharmacotherapies, as it primarily synthesizes existing literature without presenting new clinical trial data.
Evidence scorecard
- Analytic validity: Established
- Clinical validity: Partial
- Clinical utility: Not established
The evidence is based on a systematic review of clinical trials evaluating emerging obesity pharmacotherapies.